News | June 21, 2021
Zydus and Bayer announce extension of their JV
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
MEK inhibitor compound (LNP3794) developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
Researchers observed that a form of vitamin D, known as 25-hydroxyvitamin D3 (Calcifediol), was absorbed faster and better than the same dose of vitamin D.
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
First company in the world to launch Ryaltris-AZ, as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg
In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark
Lonza's Ibex Design end-to-end offering will cover the development stages of IMT-009 from development candidates through early clinical studies
Indian government is expecting pharmaceutical industry to fetch incremental sales worth Rs. 294,000 crore and exports up to Rs. 196,000 crore by FY 2027-28
The consideration to be paid will be AUD 2.0 mn for 12.5% stake.
Subscribe To Our Newsletter & Stay Updated
